$ETRM news, EnteroMedics to Host vBloc(R) Thera
Post# of 22755
Posted On: 11/30/2016 8:04:55 AM
$ETRM news,
EnteroMedics to Host vBloc(R) Therapy Commercialization and Corporate Update Conference Call
1 hour 2 minutes ago - DJNF
- Company to hold conference call today at 11:00 AM Eastern Time -
ST. PAUL, Minn., Nov. 30, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a vBloc(R) Therapy commercialization and corporate update conference call today at 11:00 AM Eastern Time ahead of the Company's anticipated special meeting of shareholders to be held Monday, December 12, 2016. The call will be led by Dan W. Gladney, the Company's President, Chief Executive Officer and Chairman of the Board.
Conference Call Details
The conference call may be accessed by dialing (877) 280-7473 (U.S. and Canada) or (707) 287-9370 (international), and entering passcode 25303017. A replay of the call will be available from November 30, 2016 at 2:00 PM Eastern Time through December 7, 2016 at 2:00 PM Eastern Time by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and entering passcode 25303017.
To access the live webcast, visit the events page of the investor relations section of EnteroMedics' website at www.enteromedics.com. A replay of the webcast will be available immediately after the conference call.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc(R) Neurometabolic Therapy, delivered by a pacemaker-like device called the vBloc(R) System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' vBloc(R) System has received U.S. Food and Drug Administration approval and CE Mark.
Information about the vBloc(R) System and vBloc(R) Neurometabolic Therapy
You should not have an implanted vBloc(R) System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the vBloc System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc Therapy and vBloc System. For additional prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc(R) System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to regain and then maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc(R) System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc(R) System; physician adoption of our vBloc(R) System and vBloc(R) Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 28, 2016. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteromedics-to-host-vbloc-therapy-commercialization-and-corporate-update-conference-call-300370127.html
SOURCE EnteroMedics Inc.
/CONTACT: Media Contact: Eliza Schleifstein, Argot Partners, (917) 763-8106, eliza@argotpartners.com; Investor Contact: Scott Youngstrom, Chief Financial Officer, EnteroMedics Inc., (651) 634-3011, syoungstrom@vbloc.com
/Web site: http://www.enteromedics.com
(END) Dow Jones Newswires
November 30, 2016 07:00 ET (12:00 GMT)
EnteroMedics to Host vBloc(R) Therapy Commercialization and Corporate Update Conference Call
1 hour 2 minutes ago - DJNF
- Company to hold conference call today at 11:00 AM Eastern Time -
ST. PAUL, Minn., Nov. 30, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a vBloc(R) Therapy commercialization and corporate update conference call today at 11:00 AM Eastern Time ahead of the Company's anticipated special meeting of shareholders to be held Monday, December 12, 2016. The call will be led by Dan W. Gladney, the Company's President, Chief Executive Officer and Chairman of the Board.
Conference Call Details
The conference call may be accessed by dialing (877) 280-7473 (U.S. and Canada) or (707) 287-9370 (international), and entering passcode 25303017. A replay of the call will be available from November 30, 2016 at 2:00 PM Eastern Time through December 7, 2016 at 2:00 PM Eastern Time by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and entering passcode 25303017.
To access the live webcast, visit the events page of the investor relations section of EnteroMedics' website at www.enteromedics.com. A replay of the webcast will be available immediately after the conference call.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc(R) Neurometabolic Therapy, delivered by a pacemaker-like device called the vBloc(R) System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' vBloc(R) System has received U.S. Food and Drug Administration approval and CE Mark.
Information about the vBloc(R) System and vBloc(R) Neurometabolic Therapy
You should not have an implanted vBloc(R) System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the vBloc System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc Therapy and vBloc System. For additional prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc(R) System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to regain and then maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc(R) System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc(R) System; physician adoption of our vBloc(R) System and vBloc(R) Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 28, 2016. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteromedics-to-host-vbloc-therapy-commercialization-and-corporate-update-conference-call-300370127.html
SOURCE EnteroMedics Inc.
/CONTACT: Media Contact: Eliza Schleifstein, Argot Partners, (917) 763-8106, eliza@argotpartners.com; Investor Contact: Scott Youngstrom, Chief Financial Officer, EnteroMedics Inc., (651) 634-3011, syoungstrom@vbloc.com
/Web site: http://www.enteromedics.com
(END) Dow Jones Newswires
November 30, 2016 07:00 ET (12:00 GMT)
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼